Exponent announces sale of BBI Group to Novo Holdings

Exponent announces that it has reached an agreement to sell BBI Group (“BBI”), a leading supplier of products and services to the global diagnostics and life sciences industries, to Novo Holdings A/S, a leading global life sciences investor, for an enterprise value of over £400 million.

Founded in 1986, BBI provides critical reagents and immunoassay development, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies to a global blue-chip customer base that includes Thermo-Fisher, Merck and Siemens. The company’s market-leading brand, BBI Solutions, provides a range of products, including antibodies, antigens, labels, complementary reagents and point of care tests. BBI is headquartered in South Wales and employs over 400 employees across its sites in seven countries and four continents. Read more

Related Posts

On the Record: Roux Institute’s Lars Perkins helps startups take off

Lars Perkins, a former software entrepreneur, Google executive and certified flight instructor who once flew planes for lifesaving “adventure philanthropy,” is managing...

28 November 2022

UNE to begin building new medical school at Portland campus

The University of New England is about to start a $93 million project to move the state’s only medical school from...

28 November 2022

Portland Planning Board recommends zoning changes for Roux Institute redevelopment

The Portland Planning Board is recommending that the city adopt zoning changes requested by the developers of a new graduate school...

22 November 2022